Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1 …
C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - jamanetwork.com
Importance Metastatic non–small cell lung cancer (mNSCLC) withEGFRexon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …
Mobocertinib: first approval
A Markham - Drugs, 2021 - Springer
Mobocertinib (EXKIVITY™) is a first-in-class EGFR tyrosine kinase inhibitor being developed
for the treatment of EGFR exon 20 insertion (EGFRex20ins)-positive non-small cell lung …
for the treatment of EGFR exon 20 insertion (EGFRex20ins)-positive non-small cell lung …
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
GJ Riely, JW Neal, DR Camidge, AI Spira, Z Piotrowska… - Cancer discovery, 2021 - AACR
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li… - Cancer discovery, 2021 - AACR
Most EGFR exon 20 insertion (EGFR ex20ins) driver mutations in non–small cell lung
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm …
Y Shi, X Hu, S Zhang, D Lv, L Wu, Q Yu… - The Lancet …, 2021 - thelancet.com
Background Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met …
(EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met …
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Purpose: We report the final analysis of JVDL (NCT02789345), which examined the
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …
[HTML][HTML] Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino… - … England Journal of …, 2017 - Mass Medical Soc
Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …
Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth …
H Akamatsu, Y Toi, H Hayashi, D Fujimoto… - JAMA …, 2021 - jamanetwork.com
Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
[HTML][HTML] Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results …
S Lu, Q Wang, G Zhang, X Dong, CT Yang… - Journal of Thoracic …, 2022 - Elsevier
Introduction Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing …
EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing …
Osimertinib for the treatment of metastatic EGFR T790M mutation–positive non–small cell lung cancer
S Khozin, C Weinstock, GM Blumenthal, J Cheng… - Clinical Cancer …, 2017 - AACR
Abstract On November 13, 2015, the FDA granted accelerated approval to osimertinib
(TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of …
(TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of …